S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
AI Stock Caught Trading Under Secret Name (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
AI Stock Caught Trading Under Secret Name (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
AI Stock Caught Trading Under Secret Name (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
AI Stock Caught Trading Under Secret Name (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
NASDAQ:VECT

VectivBio (VECT) Stock Price, News & Analysis

$16.85
0.00 (0.00%)
(As of 02/21/2024 ET)
Today's Range
$16.85
$16.85
50-Day Range
$16.85
$16.85
52-Week Range
$4.25
$16.98
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00

VECT stock logo

About VectivBio Stock (NASDAQ:VECT)

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

VECT Stock Price History

VECT Stock News Headlines

Ironwood seals the deal on VectivBio merger
Clear Buy, Sell, or Hold Recommendation on any Stock, FREE
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Clear Buy, Sell, or Hold Recommendation on any Stock, FREE
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Q2 2023 Ironwood Pharmaceuticals Inc Earnings Call
What 4 Analyst Ratings Have To Say About VectivBio Holding
See More Headlines
Receive VECT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VectivBio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/22/2024
Next Earnings (Estimated)
4/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:VECT
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.00
High Stock Price Target
$25.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+48.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$27.34 million
Book Value
$6.27 per share

Miscellaneous

Free Float
N/A
Optionable
No Data
Beta
0.08
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Luca Santarelli M.D. (Age 53)
    Founder, CEO & Director
  • Ms. Claudia D'Augusta Ph.D. (Age 53)
    Chief Financial Officer
  • Dr. Christian Meyer M.D. (Age 56)
    Ph.D., Chief Operating Officer
  • Dr. Alain Bernard Ph.D. (Age 66)
    Chief Technology Officer
  • Mr. Patrick Malloy
    Sr. VP of Investor Relations & Strategic Communications
  • Mr. Scott Applebaum (Age 56)
    Chief Legal Officer & Corp. Sec.
  • Mr. Michael Steininger
    Sr. VP & Head of HR
  • Mr. Kevin Harris M.B.A. (Age 52)
    Chief Commercial Officer
  • Dr. Sarah Holland Ph.D. (Age 60)
    Chief Bus. Officer
  • Dr. Omar Khwaja M.D. (Age 53)
    Ph.D., Chief Medical Officer














VECT Stock Analysis - Frequently Asked Questions

Should I buy or sell VectivBio stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VectivBio in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" VECT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VECT, but not buy additional shares or sell existing shares.
View VECT analyst ratings
or view top-rated stocks.

What is VectivBio's stock price target for 2024?

3 brokerages have issued 12-month price targets for VectivBio's stock. Their VECT share price targets range from $25.00 to $25.00. On average, they expect the company's stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 48.4% from the stock's current price.
View analysts price targets for VECT
or view top-rated stocks among Wall Street analysts.

How have VECT shares performed in 2024?

VectivBio's stock was trading at $16.85 at the beginning of the year. Since then, VECT stock has increased by 0.0% and is now trading at $16.85.
View the best growth stocks for 2024 here
.

When is VectivBio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 17th 2024.
View our VECT earnings forecast
.

What ETF holds VectivBio's stock ?

Range Cancer Therapeutics ETF holds 8,512 shares of VECT stock, representing 1.45% of its portfolio.

When did VectivBio IPO?

(VECT) raised $128 million in an initial public offering on Friday, April 9th 2021. The company issued 7,500,000 shares at a price of $16.00-$18.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are VectivBio's major shareholders?

VectivBio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Regency Capital Management Inc. DE (0.00%).

How do I buy shares of VectivBio?

Shares of VECT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VECT) was last updated on 2/22/2024 by MarketBeat.com Staff